產品詳情
簡單介紹：
Anti-LRFN3抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-LRFN3抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-LRFN3
Cat. Number:
Anti-LRFN3抗體KL-11088R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
LRFN3 is a 628 amino acid single-pass type I membrane protein that belongs to the LRFN family. Containing seven LRR (leucine-rich) repeats, LRFN3 also contains one fibronectin type-III domain, one Ig-like (immunoglobulin-like) domain, one LRRCT domain and one LRRNT domain. As a cell adhesion molecule that Anti-LRFN3抗體mediates homophilic cell-cell adhesion in a Ca2+-independent manner, LRFN3 promotes neurite outgrowth in hippocampal neurons. LRFN3 forms homomeric complexes across cell junctions (between adjacent cells), and can form heteromeric complexes with LRFN1, LRFN2, LRFN4 and LRFN5. The gene that encodes LRFN3 consists of more than 8,000 bases and maps to human chromosome 19q13.12.
Also known as:
SALM4; Fibronectin type II immunoglobulin and leucine rich repeat domains 1; Fibronectin type II, immunoglobulin and leucine richAnti-LRFN3抗體 repeat domains 1; FIGLER1; Leucine rich repeat and fibronectin type III domain containing 3; Leucine-rich repeat and fibronectin type-III domain-containing protein 3; Lrfn3; LRFN3_HUMAN; Synaptic adhesion-like molecule 4.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Pig, Cow, Horse, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human LRFN3/SA.
●
Predicted Molecular Weight: Anti-LRFN3抗體65kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-LRFN3抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-LRFN3抗體
Optimal working dilutions must be determined by the end user.
